-
Cys191 Palmitoylation Activates GSDMD Pyroptosis
2026-09-22
A 2024 PNAS study identifies Cys191 S-palmitoylation as a regulatory event that promotes gasdermin D membrane localization, pyroptosis, and IL-1β release. The work separates membrane targeting from later pore-assembly events and provides a mechanistic framework for studying palmitoylation in inflammatory cell death.
-
Myriocin in Sphingolipid Research Workflows
2026-09-21
Myriocin gives researchers a defined way to suppress the first committed step of sphingolipid biosynthesis and connect lipid availability with proliferation, immune signaling, and mitochondrial phenotypes. This workflow-focused guide covers dose finding, orthogonal validation, cross-domain assay design, and practical troubleshooting.
-
Stattic Workflows for STAT3 Pathway Research
2026-09-21
Stattic provides a practical way to test whether STAT3 signaling drives proliferation, apoptosis, and radiation response in HNSCC models. This guide combines product-specific handling, dose-response design, orthogonal pathway readouts, and a carefully bounded extension into keratinocyte and psoriasis research.
-
Pemetrexed Workflows for Tumor Cell Research
2026-09-20
Build reproducible Pemetrexed dose–response assays around folate-pathway inhibition, then connect growth suppression to DNA-repair phenotypes. This workflow is designed for cancer chemotherapy research, non-small cell lung carcinoma research, and malignant mesothelioma models.
-
Bradykinin: Practical Workflow and QC Guide
2026-09-19
Bradykinin (BA5201) provides a defined research peptide for studying endothelium-dependent vasodilation, vascular permeability modulation, tissue contraction, pain-related endpoints, and inflammation signaling. This guide focuses on solid handling, solution preparation, assay controls, and troubleshooting; it is not a clinical, diagnostic, or therapeutic-use protocol.
-
MLN8237 (Alisertib): Aurora A Research Guide
2026-09-19
MLN8237, also called Alisertib, is a reversible ATP-competitive Aurora A kinase inhibitor for cancer biology research. Its nanomolar biochemical potency, Aurora B selectivity, apoptosis-associated activity, and reported tumor growth inhibition support preclinical studies of mitosis and oncogenesis.
-
cgSHAPE-seq Maps SARS-CoV-2 Chimera Binding Sites
2026-09-18
The reference preprint introduces cgSHAPE-seq, a chemical-guided sequencing method that maps RNA-ligand contacts at single-nucleotide resolution. Applied to SARS-CoV-2 5′ untranslated region SL5, the approach identified a bulged guanosine recognized by coumarin derivative C30 and guided the development of RNA-degrading chimeras, including C64.
-
Lypressin Acetate: From Receptor Biology to Translation
2026-09-18
Lypressin acetate, also known as Lysine vasopressin acetate, offers translational researchers a rare opportunity to connect vasopressin receptor pharmacology with antidiuretic, vascular, hemostatic, and emerging antiviral questions. This thought-leadership analysis explains how to design fit-for-purpose assays, interpret activity data, position the peptide against other vasopressin analogs, and assess the maturity of its potential SARS-CoV-2 RdRp inhibitor hypothesis without confusing preliminary findings with clinical evidence.
-
Piezo1, Caspase-8, and Cardiac PANoptosis
2026-09-17
The reference study identifies Piezo1 as a mechanosensitive driver of myocardial ischaemia/reperfusion injury and links its activity to caspase-8-mediated cardiomyocyte PANoptosis. Its combination of cardiac injury models, pharmacological modulation, calcium measurements, and mechanistic interaction analysis provides a framework for separating channel activity from downstream cell-death signaling.
-
From Antimycobacterial SAR to Smarter PEGylation
2026-09-17
A translational strategy for connecting medicinal chemistry, amide-linked lipid architectures, and delivery-system development using DMG-PEG2000-NH2 without overstating evidence.
-
Valemetostat: Dual EZH1/2 Inhibition in ATL
2026-09-16
The reference paper explains why simultaneous EZH1 and EZH2 inhibition is a rational epigenetic strategy for adult T-cell leukemia/lymphoma (ATL), where both enzymes can sustain H3K27me3-mediated transcriptional repression. It also summarizes the phase 2 evidence supporting valemetostat, including a 48.0% overall response rate in relapsed or refractory ATL, while highlighting the need for larger comparative studies.
-
Vasopressin Analogues: Evidence and Research Implications
2026-09-15
Glavaš and colleagues review how vasopressin structure, receptor biology, and peptide engineering have produced analogues with differentiated antidiuretic, vasoconstrictive, and therapeutic profiles. The analysis is especially useful for designing receptor-aware assays and for separating established clinical applications from emerging antiviral hypotheses.
-
Lypressin Acetate: A Translational Peptide Playbook
2026-09-15
Lypressin acetate connects vasopressin receptor pharmacology with practical translational workflows spanning diabetes insipidus, vasoconstriction research, and an emerging SARS-CoV-2 RdRp inhibitor hypothesis. This article outlines how to validate mechanism, manage assay risk, and position lysine vasopressin acetate beyond the limitations of a conventional product page.
-
From ROS Signal to Translational Confidence
2026-09-14
Reactive oxygen species measurements are most valuable when fluorescence is connected to mechanism, controls, and translational decisions. This article examines how DCFH-DA-based live-cell analysis can strengthen oxidative stress studies, using recent PM2.5-induced COPD findings involving Nrf2 and EGFR/PI3K/AKT signaling as a strategic model.
-
Acridine Orange hydrochloride: Practical Staining Guide
2026-09-14
Acridine Orange hydrochloride supports membrane-permeable differential staining of DNA, RNA, and single-stranded nucleic acids for cytochemical and flow-based assays. It is appropriate for validated cell cycle analysis, apoptosis detection, and nucleic acid profiling, but not for non-nucleic-acid targets or long-term storage of prepared solutions.